In the latest issue! Structural evolution of fibril polymorphs during amyloid assembly dlvr.it/T0Zybm

Among nearly 1M in Europe getting CT scans at 10-22y (without cancer diagnosed 1y after CT) followed mean 7.8y, there was a dose-dependent response of radiation exposure to heme malignancy risk.
Would suspect higher rates of clonal hematopoiesis as well...…

An analysis of Tafamidis in Transthyretin Cardiomyopathy Clinical Trial found tafamidis 80 mg, compared w/ placebo, attenuated the decline in left ventricular systolic & diastolic function in patients w/ transthyretin amyloid cardiomyopathy over 30 mos. ja.ma/3sCAYOY

Absolutely inspired by the profound and motivational words by my mentor Joseph C Wu, MD, PhD, AHA president. Grateful for the chance to contribute to cardiovascular research in this remarkable lab. Thrilled to be part of this history! #AHA23 American Heart Association AHA Science

What a great panel and discussion! State-of-the-art of Precision Medicine and Gene Therapy in Cardiac Diseases! American Heart Association AHA Science #AHA23
#CardioTwitter #Cardiology #GeneTherapy #Heart

Great talk about gene replacement therapy for cardiac diseases by Dr. Adam Helms Adam Helms
'Next Steps: When is the Right Time for First in Human Gene Therapy? Considering the Disease and Prior Models' #AHA23 #CardioTwitter #GeneTherapy AHA Science American Heart Association

Special talk about Precision Medicine in Amyloidosis diseases by Dr. Kevin Alexander Kevin Alexander
'Amyloid: Precision Medicine at its Best - From Diagnosis to Therapeutics' #AHA23 #CardioTwitter #Amyloid #ATTR AHA Science American Heart Association

Great perspective about gene therapy for cardiac diseases by Dr. Eric Adler Eric Adler
'From Delivery to Targets: Advances in AAV Delivery and Targets on the Horizon' #AHA23 #CardioTwitter #Cardiology #GeneTherapy AHA Science American Heart Association

Special talk from Dr. Carolyn Ho Carolyn Ho about Precision Medicine. 'Precision Medicine Drives Individualized Care: How Genetics Can Inform Novel and Emerging Therapies' #AHA23 #CardioTwitter #HCM #DCM AHA Science American Heart Association

Amazing talk about the use of AI on HF diagnostic by Dr. Faraz Ahmad Faraz 'Advanced Diagnostics in HF: The Role of Artificial Intelligence, -Omics, and Deep Phenotyping' #AHA23 #CardioTwitter #AI #HFpEF AHA Science American Heart Association

Full room for the amazing talk: 'Precision Medicine and Gene Therapy in Cardiomyopathy, Heart Failure, and Beyond' #AHA23 #AHA2023 #CardioTwitter #MedTwitter #Cardiology AHA Science AHA Council on Genomic and Precision Medicine

#AHA23 is almost here!
Don't miss out on the chance to be part of our 'Precision Medicine and Gene Therapy in Cardiomyopathy, Heart Failure, and Beyond' session, along with many other exciting talks! #CardioTwitter #Cardiology #PrecisionMedicine American Heart Association AHA Science

In patients w/ cardiovascular disease & overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 mos. Full SELECT trial results: nej.md/465pj91

#AHA23 AHA Science

Let the weekend begin! #AHA23 #CardioTwitter #MedTwitter AHA Science

Antibody-Associated Reversal of ATTR Amyloidosis–Related Cardiomyopathy | NEJM nejm.org/doi/full/10.10…

#ATTR News: Intellia presents new interim data from the ongoing Phase 1 study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting for Patients and Doctors. Full details here: bit.ly/49x8UgD

#transthyretinamyloidosis

(1/10) Today the long-awaited full results from the Phase 3 ATTRibute-CM trial were presented European Society of Cardiology #ESCCongress . We already knew the topline results from last month: Acoramidis made a (big) difference in outcomes! What more did we learn?🤔Let's dig deeper...

Exciting to see these results. Many years in the making. Looking forward to the European Society of Cardiology presentation.
Here are the topline results:

edge.media-server.com/mmc/p/8wowatkw

#CardioTwitter